1448874-96-1Relevant academic research and scientific papers
SOLID FORMS OF (Z)-METHYL 3-(((4-(N-METHYL-2-(4-METHYLPIPERAZIN-L- YL)ACETAMIDO)PHENYL)AMINO)(PHENYL)METHYLENE)-2-OXO-2, 3-DIHYDRO- LH-PYRROLO[2,3-B]PYRIDINE-6-CARBOXYLATE AND SALTS THEREOF
-
, (2022/01/12)
The present disclosure provides crystalline solid forms of an antifibrotic agent, pharmaceutical compositions comprising the same, and methods of use thereof.
REDUCING FIBROSIS AND TREATING RELATED DISEASES, DISORDERS, AND CONDITIONS
-
Paragraph 0300; 0302, (2022/01/12)
Provided herein are methods of reducing fibrosis by administering methyl (Z)-3-(((4- (N-methyl-2-(4-methylpiperazin-1-yl)acetamido)phenyl)amino)(phenyl)methylene)-2-oxo-2,3- dihydro-1H-pyrrolo[2,3-b]pyridine-6-carboxylate.
ANTIFIBROTIC COMPOUNDS AND USES THEREOF
-
, (2015/11/16)
The present invention provides compounds having the general structural formula (I) and pharmaceutically acceptable derivatives thereof, as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions ther
METHODS AND USES OF COMPOUNDS FOR TREATING DISEASE
-
Paragraph 0208, (2015/04/21)
The present invention provides methods for treating polycystic kidney disease by administering a compound or pharmaceutical composition thereof having the general structural formula (I) and pharmaceutically acceptable derivatives thereof, as described generally and in classes and subclasses herein.
ANTIFIBROTIC COMPOUNDS AND USES THEREOF
-
Paragraph 000159, (2013/08/15)
The present invention provides compounds having the general structural formula (I), and pharmaceutically acceptable derivatives thereof, as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of any of a number of conditions or diseases involving abnormal or excessive fibrosis.
